The care for individuals with cystic fibrosis (CF) with at least one F508delmutation will greatly change as a result of the unparalleled clinical benefitsobserved with the new triple-combination CFTR (CF transmembraneregulator)–modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI).Incorporating ETI into the standard of care creates new motivation andopportunity to consider reductions in overall treatment burden and evaluatewhether other chronic medications can now be safely discontinued without loss ofclinical benefit. Here, CFTR is linked to cystic fibrosis.